UC Berkeley researchers have identified reactive astrocyte changes in human brain organoids modeling tuberous sclerosis complex, a rare genetic disorder associated with childhood epilepsy. Published in Nature on September 23, 2026, the UC Berkeley epilepsy study offers additional evidence about how altered glial development may be associated with seizure-related brain abnormalities.
Key Takeaways
- The UC Berkeley-led study was published in Nature on September 23, 2026
- Loss of TSC2 was associated with enlarged, pro-inflammatory reactive astrocytes in human brain organoids
- Researchers compared laboratory findings with resected brain tissue from 10 patients with tuberous sclerosis complex
- The findings suggest abnormal astrocyte development may be involved in TSC-related brain pathology
- The research remains experimental and does not establish a new epilepsy treatment
UC Berkeley Epilepsy Study Examines the Role of Astrocytes
A UC Berkeley-led research team has found evidence that abnormal astrocytes may be involved in early brain changes associated with tuberous sclerosis complex, rather than appearing only after chronic seizure activity.
The study, published in Nature on September 23, examined how mutations affecting the TSC pathway influence cell development in human brain organoids. Researchers found that loss of the TSC2 gene was associated with developing neural cells becoming enlarged, reactive astrocytes with inflammatory characteristics.
Tuberous sclerosis complex, or TSC, is a rare genetic disorder caused by variants in the TSC1 or TSC2 genes. The condition can produce noncancerous lesions in the brain and other organs, while seizures are among its common neurological effects. The genes help regulate the mTOR pathway, which is involved in cell growth and development.
The research offers additional detail on how those genetic changes may be associated with abnormalities in developing brain tissue. The researchers focused in part on astrocytes, glial cells that support brain function and help regulate the environment surrounding neurons.
Their results showed that reactive astrocytes appeared early during development in the experimental models, before seizure activity could account for the observed changes. The findings suggest astrocyte dysfunction may be one component of the biological processes associated with TSC.
UC Berkeley’s research activity also includes work in other health fields, including UC Berkeley dengue research examining conditions that could influence mosquito-borne disease risks in California.
Brain Organoids Traced Changes Associated With TSC2 Loss
The researchers created cortical brain organoids from human stem cells and introduced genetic changes designed to model mutations involved in TSC.
Brain organoids are small, laboratory-grown collections of cells that reproduce selected features of developing human brain tissue. They do not reproduce the full complexity of a human brain, but they allow researchers to observe specific cellular processes in a controlled setting.
In the UC Berkeley experiments, researchers tracked cells carrying TSC2 mutations as the organoids developed. Single-cell analysis indicated that cells lacking functional TSC2 increasingly developed along glial pathways, including into astrocytes.
Those astrocytes were enlarged and displayed characteristics associated with a reactive, pro-inflammatory state. The study also identified reduced expression of glutamate transporters, increased inflammatory cytokine secretion and elevated expression of proteins including APOE and clusterin in affected astrocytes.
The team also conducted experiments involving TSC1, the other gene associated with tuberous sclerosis complex. Those organoids showed an increased ratio of astrocytes to neurons during early developmental stages, providing additional evidence of a relationship between disruption of the TSC pathway and altered glial development.
“Developing the organoid system was a big advance in our ability to more closely mimic patient brain phenotypes,” UC Berkeley professor Helen Bateup said.
The models allowed researchers to examine genetic effects without the influence of a patient’s history of repeated seizures. The early appearance of reactive astrocytes suggests that the cells may be involved in underlying developmental processes associated with TSC, although the experiments do not establish how strongly those changes contribute to epilepsy in patients.
Reactive Astrocytes Appeared Early in Brain Development
Astrocytes perform several supporting functions in the nervous system. They help maintain the chemical environment surrounding neurons and contribute to processes involved in neural signaling.
The UC Berkeley epilepsy study found that TSC-related genetic changes were associated with altered astrocyte development in the experimental models.
According to the Nature paper, loss of TSC2 caused neural progenitor cells to produce enlarged, reactive astrocytes through a cell-autonomous process. The findings indicate that at least some of the observed cellular changes can arise within cells carrying the mutation rather than appearing solely as a response to later seizure activity.
Abnormal glial cells have previously been observed in cortical tubers, the focal brain malformations associated with TSC. Researchers have continued studying whether those cells contribute to neurological abnormalities or develop partly in response to seizures and changes in affected brain tissue.
The organoid experiments support the possibility that reactive astrocytes can emerge directly from TSC-related genetic disruption during development.
However, the findings do not establish that astrocytes are a primary cause of epilepsy in TSC. They also cannot be assumed to apply to other types of childhood epilepsy, which can have different genetic and biological origins.
Patient Tissue Provided Additional Supporting Evidence
The research team also studied surgically removed cortical tuber tissue from 10 patients with tuberous sclerosis complex.
The patient samples allowed researchers to compare characteristics identified in the experimental models with cells found in human brain lesions.
Using cyclic immunostaining, the researchers identified cells in the patient tissue with high mTORC1 activity and reactive astrocyte markers. The Nature study reported a cell population with expression characteristics similar to those found in the organoid models.
Because organoids reproduce only selected elements of human brain development, the patient-tissue comparison provided an additional source of evidence that some of the cellular patterns observed in the models may also occur in people with TSC.
The two types of evidence remain different. Patient tissue reflects established disease, while organoids model selected developmental processes under laboratory conditions. Together, they provide complementary information about cellular changes associated with tuberous sclerosis complex.
Biomedical research across California universities also includes programs such as UC Davis cancer research involving clinical research, population health and research infrastructure.
The Findings Identify an Area for Further Research
The identification of reactive astrocytes gives researchers a more specific cell type to examine in studies of TSC-related epilepsy.
Current treatment approaches for TSC-associated seizures can include antiseizure medications, mTOR inhibitors and, in some cases, epilepsy surgery. The National Institute of Neurological Disorders and Stroke notes that everolimus, an mTOR inhibitor, is approved for intractable seizures associated with TSC, while surgery may be considered for some patients whose seizures remain difficult to control.
The UC Berkeley study does not change those treatment recommendations. Instead, it suggests that abnormal astrocyte activity may warrant further investigation as part of the broader biological processes involved in TSC.
Researchers have noted that broad inhibition of the mTOR pathway can affect multiple metabolic, immune and cellular functions because mTOR signaling has roles throughout the body. Future studies may therefore examine whether more selective approaches involving abnormal astrocyte activity are biologically feasible.
At this stage, the research does not show that targeting astrocytes would reduce seizures or improve clinical outcomes. Such questions would require additional laboratory research and, if supported by later evidence, eventual clinical evaluation.
Brain Organoid Findings Have Important Limits
Human brain organoids allowed researchers to examine developmental processes that are difficult to study directly in patients.
The models also reproduce only part of the biological complexity of the human brain.
Organoids contain a subset of the cells and structures present in human brain tissue. They do not reproduce complete neural circuitry, blood circulation, the full immune environment or the clinical history of a person living with epilepsy.
The study’s findings are also specifically related to tuberous sclerosis complex and disruption of the TSC-mTOR pathway. They should not be generalized to all forms of epilepsy.
TSC is one of many conditions that can be associated with seizures. The research therefore provides evidence about a specific genetic disorder rather than a general explanation for childhood epilepsy.
The Research Defines New Questions for TSC Epilepsy Studies
The UC Berkeley epilepsy study provides researchers with a possible sequence of biological events to examine further, including TSC gene disruption, increased mTORC1 signaling, altered glial development and the appearance of reactive astrocytes.
The combined organoid and patient-tissue findings support an association between astrocyte changes and the underlying biology of tuberous sclerosis complex. They do not determine how much those cells contribute to seizure development or severity.
Further research will be needed to clarify whether similar mechanisms occur across larger groups of patients, how astrocyte activity interacts with neurons and other cell types, and whether modifying these pathways could eventually have therapeutic relevance.
For now, the findings add to understanding of how TSC-related genetic changes may affect developing human brain cells and identify astrocytes as a specific subject for continued research into TSC-associated childhood epilepsy.
Frequently Asked Questions
What did the UC Berkeley epilepsy study find?
The UC Berkeley epilepsy study found that loss of TSC2 was associated with enlarged, pro-inflammatory reactive astrocytes in human brain organoids. Researchers also identified related cellular characteristics in surgically removed tissue from patients with tuberous sclerosis complex.
Why are astrocytes important in the study?
Astrocytes are glial cells that support normal brain function and help regulate the environment around neurons. Their early appearance in a reactive state suggests they may be involved in biological processes associated with TSC, although their precise contribution to seizures remains under investigation.
How were brain organoids used in the research?
Researchers created human stem-cell-derived cortical organoids carrying genetic changes associated with tuberous sclerosis complex. The models allowed the team to study how those changes were associated with the development of neurons and glial cells under controlled laboratory conditions.
What did researchers find in patient tissue?
Researchers examined surgically removed tuber tissue from 10 patients with tuberous sclerosis complex. They identified cellular and protein-expression characteristics that were similar to patterns observed in the organoid experiments.
Does the study establish a new treatment for childhood epilepsy?
No. The study identifies cellular changes that may help guide future research, but it does not establish a new treatment for TSC-associated childhood epilepsy. Additional experimental and clinical evidence would be needed before any astrocyte-focused approach could be considered a treatment.
Disclaimer
This article summarizes findings from experimental research and is intended for informational purposes only. The study does not establish a new treatment for epilepsy, and its findings should not be interpreted as medical advice or as evidence that the identified cellular changes cause all cases of epilepsy. Patients and caregivers should consult qualified healthcare professionals regarding diagnosis, treatment and individual medical decisions.
